Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).

被引：7
|
作者：
Dang, Nam H.
Ogura, Michinori
Castaigne, Sylvie
Fayad, Luis
Jerkeman, Mats
Radford, John A.
Pezzutto, Antonio
Bondarenko, Igor
Stewart, Douglas Allan
Shnaidman, Michael
Sullivan, Sharon
Vandendries, Erik
Tobinai, Kensei
Ramchandren, Rod
Hamlin, Paul A.
Gine, Eva
Ando, Kiyoshi
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
[3] Hosp Versailles, Versailles, France
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Skane Univ Hosp, Lund, Sweden
[6] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[7] Charite, Dept Hematol Oncol & Tumor Immunol, D-13353 Berlin, Germany
[8] Municipal Clin Hosp 4, State Med Acad, Dnepropetrovsk, Ukraine
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Pfizer Inc, New York, NY USA
[11] Pfizer, Cambridge, MA USA
[12] Pfizer Inc, Cambridge, MA USA
[13] Natl Canc Ctr, Tokyo, Japan
[14] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[16] Hosp Quiron Barcelona, Inst Oncol Baselga, Unidad Hematol, Barcelona, Spain
[17] Tokai Univ, Sch Med, Univ Hosp, Hiratsuka, Kanagawa 25912, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Ogura, Michinori
    Castaigne, Sylvie
    Fayad, Luis E.
    Jerkeman, Mats
    Radford, John
    Pezzutto, Antonio
    Bondarenko, Igor
    Stewart, Douglas A.
    Shnaidman, Michael
    Sullivan, Sharon
    Vandendries, Erik
    Tobinai, Kensei
    Ramchandren, Radhakrishnan
    Hamlin, Paul A.
    Gine, Eva
    Ando, Kiyoshi
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) : 583 - 586
  • [2] INOTUZUMAB OZOGAMICIN IN B-CELL NON-HODGKIN'S LYMPHOMA REFRACTORY TO RITUXIMAB plus CHEMOTHERAPY OR RADIOIMMUNOTHERAPY
    Ogura, M.
    Leach, J.
    Egyed, M.
    Ando, K.
    Hatake, K.
    Tobinai, K.
    Feldman, T.
    Hua, S.
    Volkert, A.
    Vandendries, E.
    Goy, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [3] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Sangha, Randeep
    Davies, Andrew
    Dang, Nam H.
    Ogura, Michinori
    MacDonald, David A.
    Volkert, Angela
    Ananthakrishnan, Revathi
    Luu, Kenneth
    Boni, Joseph P.
    Vandendries, Erik
    Goh, Yeow-Tee Y. T.
    BLOOD, 2013, 122 (21)
  • [5] Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+B-cell non-Hodgkin lymphoma (B-NHL).
    Sangha, Randeep S.
    Davies, Andrew John
    Dang, Nam H.
    Ogura, Michinori
    Paccagnella, M. Luisa
    Ananthakrishnan, Revathi
    Vandendries, Erik
    Tee, Goh Yeow
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] INOTUZUMAB OZOGAMICIN IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY TO RITUXIMAB AND CHEMOTHERAPY OR RADIOIMMUNOTHERAPY
    Goy, A.
    Leach, J.
    Tsai, M.
    Foran, J.
    Forero, A.
    Wagner-Johnston, N.
    Ehmann, C.
    Egyed, M.
    Ando, K.
    Hatake, K.
    Tobinai, K.
    Feldman, T.
    Vandendries, E.
    Volkert, A.
    Wang, S. L.
    Ogura, M.
    HAEMATOLOGICA, 2012, 97 : 324 - 324
  • [7] Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Ogura, Michinori
    Hatake, Kiyohiko
    Ando, Kiyoshi
    Tobinai, Kensei
    Tokushige, Kota
    Ono, Chiho
    Ishibashi, Taro
    Vandendries, Erik
    CANCER SCIENCE, 2012, 103 (05) : 933 - 938
  • [8] A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
    Goy, Andre
    Forero, Andres
    Wagner-Johnston, Nina
    Ehmann, W. Christopher
    Tsai, Michaela
    Hatake, Kiyohiko
    Ananthakrishnan, Revathi
    Volkert, Angela
    Vandendries, Erik
    Ogura, Michinori
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (04) : 571 - 581
  • [9] INOTUZUMAB OZOGAMICIN (INO, CMC-544) IN PTS WITH INDOLENT B-CELL NHL REFRACTORY TO RITUXIMAB (R), R PLUS CHEMOTHERAPY, OR RADIOIMMUNOTHERAPY (RIT)
    Goy, A.
    Leach, J.
    Ehmann, W. C.
    Egyed, M.
    Ando, K.
    Hatake, K.
    Tobinai, K.
    Feldman, T.
    Hua, S.
    Volkert, A.
    Vandendries, E.
    Ogura, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 105 - 105
  • [10] Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
    Villasboas, Jose Caetano
    Kline, Justin Paul
    Lazaryan, Aleksandr
    Bartlett, Nancy L.
    Hernandez-Ilizaliturri, Francisco J.
    Awan, Farrukh Tauseef
    Geethakumari, Praveen Ramakrishnan
    Karmali, Reem
    Shune, Leyla
    Lansigan, Frederick
    Reeder, Craig B.
    Diefenbach, Catherine S. Magid
    Sharon, Elad
    Atherton, Pamela J.
    Fiskum, Jack
    Yin, Jun
    Adjei, Alex A.
    Ansell, Stephen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
12345